Korsana Biosciences, Inc. (KRSA)
37.31
+1.86
(+5.25%)
USD |
NASDAQ |
Nov 20, 10:36
Korsana Biosciences Cash from Investing (Quarterly) : -0.231M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.231M |
| June 30, 2026 | 0.00 |
| March 31, 2026 | -0.066M |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 10.40M |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | -0.007M |
| June 30, 2021 | 0.002M |
| March 31, 2021 | 1.462M |
| December 31, 2020 | 1.436M |
| September 30, 2020 | 0.003M |
| June 30, 2020 | -0.065M |
| March 31, 2020 | -1.356M |
| December 31, 2019 | -0.10M |
| September 30, 2019 | -0.554M |
| June 30, 2019 | -4.247M |
| March 31, 2019 | -1.814M |
| December 31, 2018 | -1.816M |
| September 30, 2018 | -1.16M |
| June 30, 2018 | -0.30M |
| March 31, 2018 | -0.162M |
| December 31, 2017 | -0.436M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Q32 Bio, Inc. | -0.052M |
| IRulya Therapeutics, Inc. | -67.79M |
| Climb Bio, Inc. | 6.40M |
| PepGen Inc. | 12.46M |
| Bridgebio Oncology Therapeutics, Inc. | 50.34M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -46.83M |
| Cash from Financing (Quarterly) | 351.10M |
| Free Cash Flow | -51.31M |
| Free Cash Flow Per Share (Quarterly) | -3.479 |
| Free Cash Flow to Equity (Quarterly) | -48.33M |
| Free Cash Flow to Firm (Quarterly) | -47.06M |
| Free Cash Flow Yield | -3.02% |